May 9, 2017 09:04 AM EDT

Recro Pharma tees up an NDA for its COX-2 pain drug following positive PhIII program

Arsalan Arif

Founder

Little, Malvern, PA-based Recro Pharma $REPH posted positive Phase III data for the IV formulation of their pain therapy meloxicam. Shares bumped up 10 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Recro Pharma tees up an NDA for its COX-2 pain drug following positive PhIII program

Arsalan Arif

Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio ends development of gene therapy for adrenal gland disorder

Sanofi, Regeneron to refile Dupixent for skin condition after new study win

Exclusive: A male contraceptive may prevent 99% of pregnancies. Now it’s up to a small biotech to finish testing it

Radiant Bio snags $35M for antibody platform, with GSK and Regeneron partnerships

Novo's oral amycretin could lead to more weight loss beyond 12 weeks, according to early-stage trial

GSK discontinues herpes therapeutic vaccine after Phase 2 disappointment

Re­cro Phar­ma tees up an NDA for its COX-2 pain drug fol­low­ing pos­i­tive PhI­II pro­gram

Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Recro Pharma tees up an NDA for its COX-2 pain drug following positive PhIII program